News
TENX
3.480
-3.33%
-0.120
Weekly Report: what happened at TENX last week (0415-0419)?
Weekly Report · 4d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning. Tian Ruixiang stock is rocketing 151% after announcing plans for an extraordinary general shareholders meeting. MicroCloud Hologram shares are soaring over 52% with heavy pre-market trading. Moving stocks this morning are earnings reports, shareholder meetings, public offerings and more.
Investorplace · 04/18 11:27
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Alcoa Corporation rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter. The company shares jumped 3% to $36.60 in pre- market trading. Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) shares gained 155.6% in today's trading.
Benzinga · 04/18 10:28
Weekly Report: what happened at TENX last week (0408-0412)?
Weekly Report · 04/15 09:36
Weekly Report: what happened at TENX last week (0401-0405)?
Weekly Report · 04/08 09:38
Weekly Report: what happened at TENX last week (0325-0329)?
Weekly Report · 04/01 09:37
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023
Tenax Therapeutics reported earnings per share of -$11.84 for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for -$8.14. Tenax Therapedutics reported results for the last quarter of 2018.
Investorplace · 03/29 01:54
Tenax Therapeutics: Q4 Earnings Insights
Tenax Therapeutics reported its Q4 earnings results on March 28. The company missed estimated earnings by -45.0%. Tenax TherAPEutics is expected to report its earnings on Thursday, March 28, 2024 at 08:30am. Last quarter the company beat on EPS by $1.6 and was followed by a 19.0% drop in the shares.
Benzinga · 03/28 21:05
Tenax Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Tenax Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $12.98 per share. The mean expectation of two analysts was for a loss of $8.14 per share in the same quarter. Reported revenue was zero; analysts expected zero.
Reuters · 03/28 21:02
Tenax Therapeutics Q4 EPS $(11.84) Misses $(8.14) Estimate
Benzinga · 03/28 21:01
Tenax Therapeutics GAAP EPS of -$31.04
Tenax Therapeutics reported cash and cash equivalents of $9.8 million as of December 31, 2023. The Company raised approximately $8.0 million in a registered public offering in February 2024. The company reported FY GAAP EPS of -$31.04.
Seeking Alpha · 03/28 12:44
*Tenax Therapeutics 2023 Loss/Shr $31.04 >TENX
Dow Jones · 03/28 12:40
*Tenax Therapeutics 2023 Loss $7.7M >TENX
Dow Jones · 03/28 12:39
Weekly Report: what happened at TENX last week (0318-0322)?
Weekly Report · 03/25 09:39
Weekly Report: what happened at TENX last week (0311-0315)?
Weekly Report · 03/18 09:38
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Fangdd Network Group Ltd. Rose sharply in today’s pre-market trading. The company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector. Kidpik Corp. Shares rose 311% to $11.10 in pre- market trading.
Benzinga · 03/11 12:08
Weekly Report: what happened at TENX last week (0304-0308)?
Weekly Report · 03/11 09:37
Weekly Report: what happened at TENX last week (0226-0301)?
Weekly Report · 03/04 09:38
Weekly Report: what happened at TENX last week (0219-0223)?
Weekly Report · 02/26 09:41
More
Webull provides a variety of real-time TENX stock news. You can receive the latest news about Tenax Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).